Fig. 6

Vitamin C relieves the re-activation of MAPK/ERK and PI3K/AKT pathways caused by PLX4032. a The indicated cells were treated with PLX4032 4 μM for 0, 6, 12, 24 h, and cell lysates were then subjected to western blot analysis to determine the re-activation of MAPK/ERK as well as PI3K/AKT pathways (left panels). The normalized band intensity of Pan-AKT and pERK were shown in right panels. b The indicated cells were treated with PLX4032 4 μM and Vitamin C 0.5 mM (VC) for 0, 12, 24 h, and cell lysates were then subjected to western blot analysis to determine the re-activation of MAPK/ERK as well as PI3K/AKT pathways (left panels). The normalized band intensity of Pan-AKT and pERK were shown in right panels. β-Actin/tERK was used for normalizing Pan-AKT/pERK. c A comparison of the levels of p-ERK by IHC staining in xenografts slices. The expression levels were calculated with IOD value (right panels). Scale bars, 200 μm. Data were presented as mean ± SD. ns, not significant; *, P < 0.05; **, P < 0.01; ***/^^^/###, P < 0.001. */ns: compared with control group; ^: compared with VC group; #: compared with PLX4032 group